Global News

Purdue Pharma stops pushing opioids

Purdue Pharma stops pushing opioids

Opioid overdose killed more than 42,000 Americans in 2016, and McCaskill cited state statistics showing that in Missouri that year, about 60 percent of the 1,300 drug overdose deaths came from opioids.

Even though Purdue Pharma is going to stop marketing opioids to medical professionals, they are still going to manufacture and sell their pain-killers to pharmacies.

More than 42,000 people died in 2016 of overdoses from prescription drugs, fentanyl and heroin, according to number released late past year by the National Center for Health Statistics. Moving forward, any requests for information will be handled by Purdue's medical affairs team, the company said.

Purdue "vigorously denies" any misconduct, saying it has consistently followed the CDC's opioid guidelines including not recommending opioids as a first option.

The tactics highlighted in Monday's report are at the heart of lawsuits filed by hundreds of state and local governments against the opioid industry.

Purdue has also developed Hysingla, another opioid that lasts longer than its predecessor.

Dozens of lawsuits across the country allege that Purdue Pharma launched a fraudulent marketing scheme to boost sales of OxyContin in the late 1990s that downplayed the risks for addiction from pain medication.

Using her position of a key Senate committee, McCaskill says she is looking into the financial relationships between the pharmaceutical companies that make powerful painkillers and the doctors and organizations that have defended and promoted their use.

The Sackler family owns Purdue Pharma, and has accumulated a fortune estimated at about $14 billion dollars by Forbes in 2015, by distributing the highly addictive- and deadly- opioid painkiller OxyContin as a purportedly non-addictive version of oxycodone.

He said that he thinks the decision by Purdue Pharma will have little to no impact on pharmacies like his. Purdue said in a statement that it supported organisations interested in helping patients receive appropriate care.

Insys Therapeutics, a company recently targeted by federal prosecutors, provided more than $3.5 million to interest groups and physicians, according to McCaskill's report. Along with its pullback from opioid marketing, it launched an ad campaign at the end of a year ago that involved taking out full-page ads in national newspapers promoting its efforts to address the opioid epidemic.